ABLE Human Motion (ABLE), ES

ABLE Human Motion is a Barcelona-based company that designs, develops, manufactures and commercializes innovative robotic exoskeletons to improve the mobility, health and quality of life of people with disabilities. The company was created in late 2018 as a spin-off of the Polytechnic University of Catalonia (UPC), with the aim of democratising exoskeleton technology so more patients can benefit from robotic rehabilitation.
Our first product is the ABLE Exoskeleton: a lightweight, quick to adjust and accessible robotic exoskeleton for gait rehabilitation in the clinical setting. The device is the result of collaborating with hundreds of clinical professionals and patients, integrating their feedback into the design of the product to better address their needs. After completing clinical trials in leading neurorehabilitation hospitals in Germany, the Netherlands and Spain, the ABLE Exoskeleton obtained the CE mark as a medical device and began its commercialization in 2024.
The company has an ISO13485-certified Quality Management System as a medical device manufacturer and is a member of the International Industry Society for Advanced Rehabilitation Technology (IISART). Our technology has been featured in national and international media (Forbes, Financial Times), receiving awards such as Best European Robotics Startup (ERF) and Innovators Under 35 (MIT Technology Review).

Project director on behalf of ABLE is Alfons Carnicero Carmona, CEO.

​The role of ABLE Human Motion in the consortium is to provide one of the three demonstrators of the technology: the NerveABLE, a bilateral robotic exoskeleton that will connect bidirectionally with the implantable neural system developed in the project. We are also directly involved in integrating the device with the implantable electrodes and the validation tests of the system.